BMO Capital Raises Globe Life (GL) PT to $149 on Strong D2C Performance

Globe Life Inc. (NYSE:GL) is one of the most undervalued quality stocks to buy according to hedge funds. On July 24, Globe Life released its Q2 2025 earnings. BMO Capital analyst Jack Matten subsequently raised the firm’s price target on Globe Life to $149 from $114 on July 30, while maintaining a Market Perform rating. The adjustment was made due to positive underlying trends in the company’s D2C division, which uses leads and analytics to support exclusive agency sales.

Globe Life reported a net income of $253 million, or $3.05 per share, in Q2, which is a slight decrease from the $258 million, or $2.83 per share, reported a year ago. However, net operating income increased by 10% to $271 million, or $3.27 per share, up from $2.97 per share the previous year.

BMO Capital Raises Globe Life (GL) PT to $149 on Strong D2C Performance

15 States with the Best Healthcare in the US

The company’s Life Insurance premium revenue grew by 3% to $840 million, while the Life underwriting margin increased by 6% to $340 million. However, Health Insurance premium revenue grew by 8% to $378 million, but the Health underwriting margin dropped by 2% to $98 million.

Globe Life Inc. (NYSE:GL) provides various life and supplemental health insurance products, and annuities to lower-middle- and middle-income families in the US.

While we acknowledge the potential of GL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.